Patent 10155987 was granted and assigned to Dana-Farber Cancer Institute on December, 2018 by the United States Patent and Trademark Office.
This present invention provides methods of treating of assessing/monitoring the responsiveness of a cancer cell to JAK inhibitor therapy.